Acalculous Cholecystitis Market

Market Overview:

The 7 major acalculous cholecystitis markets reached a value of US$ 330 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 850 Million by 2034, exhibiting a growth rate (CAGR) of 8.99% during 2024-2034.

The acalculous cholecystitis market has been comprehensively analyzed in IMARC's new report titled "Acalculous Cholecystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acalculous cholecystitis (AC) refers to a medical condition of acute inflammation and distention of the gallbladder without any evidence of gallstones or cystic duct obstruction. The symptoms of acalculous cholecystitis can be similar to those of calculous cholecystitis, but in this case, there are no stones present in the gallbladder. Some of the common signs indicative of acalculous cholecystitis are severe abdominal pain, which is typically located in the right upper quadrant or epigastric region, nausea, vomiting, fever, jaundice, loss of appetite, tenderness in the abdomen, etc. The diagnosis of the ailment usually involves a combination of clinical evaluation and imaging tests. The physician generally starts by obtaining a thorough medical history and performing a physical exam to assess for symptoms such as abdominal pain, tenderness, and fever. Numerous imaging tests, including an abdominal ultrasound or computed tomography (CT) scan, are used to confirm the diagnosis and evaluate the severity of the condition. Additionally, blood tests are also utilized to assess for signs of infection or inflammation.

The rising incidences of several associated risk factors, such as gallbladder injury, bacterial infections, ischemia, etc., which cause gallbladder inflammation, are primarily driving the acalculous cholecystitis market. In addition to this, the escalating utilization of percutaneous cholecystostomy for draining the gallbladder in order to relieve symptoms of AC and prevent complications, including gangrene or perforation of the gallbladder, is further bolstering the market growth. Moreover, the widespread adoption of endoscopic retrograde cholangiopancreatography (ERCP) for identifying biliary obstruction, which can help to alleviate symptoms and prevent complications, is also augmenting the market. Apart from this, the increasing usage of magnetic resonance cholangiopancreatography (MRCP), a non-invasive imaging modality, to visualize the bile ducts and pancreas for confirming AC in cases where the ultrasound is inconclusive, is creating a positive outlook for the market. Additionally, several key players are making extensive investments in the development of narrow-spectrum antibiotics to target specific pathogens and minimize the effect of resistance. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of laparoscopic cholecystectomy on account of its numerous associated benefits, such as reduced scarring, quicker recovery, and a shorter hospital stay compared to open surgery procedures, is expected to drive the acalculous cholecystitis market during the forecast period.

IMARC Group’s new report provides an exhaustive analysis of the acalculous cholecystitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acalculous cholecystitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acalculous cholecystitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acalculous cholecystitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acalculous cholecystitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acalculous cholecystitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the acalculous cholecystitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acalculous cholecystitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acalculous cholecystitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of acalculous cholecystitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acalculous cholecystitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acalculous cholecystitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with acalculous cholecystitis across the seven major markets?
• What is the size of the acalculous cholecystitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acalculous cholecystitis?
• What will be the growth rate of patients across the seven major markets?
   

Acalculous Cholecystitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acalculous cholecystitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acalculous cholecystitis market?
• What are the key regulatory events related to the acalculous cholecystitis market?
• What is the structure of clinical trial landscape by status related to the acalculous cholecystitis market?
• What is the structure of clinical trial landscape by phase related to the acalculous cholecystitis market?
• What is the structure of clinical trial landscape by route of administration related to the acalculous cholecystitis market?